This report covers the 68 geographical markets and provides an Excel-based forecast model for the Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity market through 2033.
Across the 68 markets, sales in the GLP1-RA market in the type 2 diabetes and obesity space were $39.2 billion in 2023, growing to $168.1 billion in 2033.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 79.8% and 74.4% of 68-market sales in 2023 and 2033, respectively.
Across the 68 markets, sales in the GLP1-RA market in the type 2 diabetes and obesity space were $39.2 billion in 2023, growing to $168.1 billion in 2033.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 79.8% and 74.4% of 68-market sales in 2023 and 2033, respectively.
Scope
- This publication is an expanded version of the Excel model containing the patient-based forecast sales for Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity, covered in the analyst’s report “Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: Seven -Market Drug Forecast and Market Analysis”, published in April 2024. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- About the Analyst
1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology
2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders interviewed for this report
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Analyst
2.5.2 Therapy area directors
2.5.3 Epidemiologist
2.5.4 Epidemiology reviewers
2.5.5 Vice President of Disease Intelligence and Epidemiology
2.5.6 Global Head and EVP of Healthcare Operations and Strategy
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Regeneron
- Bayer
- Roche
- Novartis
- AbbVie
- RegenxBio
- Outlook Therapeutics
- Kodiak Sciences
- Opthea
- Apellis Pharmaceuticals
- Iveric Bio
- Genentech
- Chugai
- Bausch + Lomb
- Clinigen
- Cheplapharm
- Ribomic
- Unity Biotechnology
- Clearside Biomedical
- EyePoint Pharmaceuticals
- Ocular Therapeutix
- Ashvattha Therapeutics
- Outlook Therapeutics
- Adverum Biotechnlologies
- Formycon
- Essex Bio
- Xbrane Biopharma
- Celltrion
- Lupin
- Viatris
- Amgen
- Samsung Bioepis
- Senju
- SamChunDang Pharm Co Ltd
